BRPI0810163A2 - Vetor de adenovírus de símio defeituoso de replicação recombinante, composição imunogênica, método para desencadear uma resposta imune contra a proteína de adesão relacionada com trombospondina, kit ou combinação de produto, e, uso de um vetor de adenovírus de símio defeituoso em replicação recombinante - Google Patents

Vetor de adenovírus de símio defeituoso de replicação recombinante, composição imunogênica, método para desencadear uma resposta imune contra a proteína de adesão relacionada com trombospondina, kit ou combinação de produto, e, uso de um vetor de adenovírus de símio defeituoso em replicação recombinante

Info

Publication number
BRPI0810163A2
BRPI0810163A2 BRPI0810163A BRPI0810163A2 BR PI0810163 A2 BRPI0810163 A2 BR PI0810163A2 BR PI0810163 A BRPI0810163 A BR PI0810163A BR PI0810163 A2 BRPI0810163 A2 BR PI0810163A2
Authority
BR
Brazil
Prior art keywords
veterinus
adbusion
thrombospondine
trigging
recruit
Prior art date
Application number
Other languages
English (en)
Inventor
Arturo Reyes
Adrian Hill
Geraldine O'hara
Stefano Colloca
Riccardo Cortese
Original Assignee
Isis Innovation
Okairos Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation, Okairos Ag filed Critical Isis Innovation
Publication of BRPI0810163A2 publication Critical patent/BRPI0810163A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0810163 2007-04-10 2008-04-10 Vetor de adenovírus de símio defeituoso de replicação recombinante, composição imunogênica, método para desencadear uma resposta imune contra a proteína de adesão relacionada com trombospondina, kit ou combinação de produto, e, uso de um vetor de adenovírus de símio defeituoso em replicação recombinante BRPI0810163A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0706914A GB0706914D0 (en) 2007-04-10 2007-04-10 Novel adenovirus vectors
GB0717888A GB0717888D0 (en) 2007-04-10 2007-09-13 Adenoviral vector encoding malaria antigen
PCT/GB2008/001175 WO2008122769A2 (en) 2007-04-10 2008-04-10 Adenoviral vector encoding malaria antigen

Publications (1)

Publication Number Publication Date
BRPI0810163A2 true BRPI0810163A2 (pt) 2015-01-06

Family

ID=38091120

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810163 BRPI0810163A2 (pt) 2007-04-10 2008-04-10 Vetor de adenovírus de símio defeituoso de replicação recombinante, composição imunogênica, método para desencadear uma resposta imune contra a proteína de adesão relacionada com trombospondina, kit ou combinação de produto, e, uso de um vetor de adenovírus de símio defeituoso em replicação recombinante

Country Status (11)

Country Link
US (3) US9895431B1 (pt)
EP (3) EP2486939B1 (pt)
JP (1) JP5505937B2 (pt)
CN (1) CN101848729A (pt)
AU (1) AU2008235363B2 (pt)
BR (1) BRPI0810163A2 (pt)
CA (1) CA2683679A1 (pt)
ES (2) ES2638577T3 (pt)
GB (2) GB0706914D0 (pt)
MX (1) MX2009010870A (pt)
WO (2) WO2008122769A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
CA2679410C (en) * 2007-03-02 2017-01-17 Glaxosmithkline Biologicals S.A. Novel method and compositions
CA2707245A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Vaccine
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
CA2769996C (en) * 2009-11-05 2018-06-12 The United States Of America As Represented By The Secretary Of The Na Plasmodium falciparum sporozoite and liver stage antigens
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
CN103923943B (zh) * 2013-08-19 2019-01-22 中国科学院上海巴斯德研究所 一种基于腺病毒AdC7的表达载体及其构建方法
HUE043042T2 (hu) 2013-11-01 2019-07-29 Pfizer Vektorok prosztatához kapcsolódó antigének expressziójára
US11571472B2 (en) 2014-06-13 2023-02-07 Glaxosmithkline Biologicals Sa Immunogenic combinations
KR102535670B1 (ko) * 2015-06-12 2023-05-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 아데노바이러스 폴리뉴클레오티드 및 폴리펩티드
US11065320B2 (en) * 2016-04-12 2021-07-20 Oxford University Innovation Limited Prime target
US10953108B2 (en) * 2016-08-01 2021-03-23 The Wistar Institute Of Anatomy And Biology Compositions and methods of replication deficient adenoviral vectors for vaccine applications
TW201907937A (zh) 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
JP7653013B2 (ja) 2018-01-04 2025-03-28 アイコニック セラピューティクス リミテッド ライアビリティ カンパニー 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
GB201818084D0 (en) 2018-11-06 2018-12-19 Univ Oxford Innovation Ltd Compositions and methods
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
EP4117723A1 (en) 2020-03-13 2023-01-18 Oxford University Innovation Limited Compositions and methods for inducing an immune response
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES
WO2022056488A1 (en) * 2020-09-14 2022-03-17 Genprex, Inc. Nonviral vectors for increasing fas expression in cancer cells and methods of use thereof
GB202016604D0 (en) 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
WO2022234283A1 (en) 2021-05-07 2022-11-10 Astrazeneca Uk Limited Compositions and methods for inducing an immune response

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
WO2001002607A1 (en) * 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
GB9922361D0 (en) * 1999-09-21 1999-11-24 Isis Innovation Generating an immune response to an antigen
US8071322B2 (en) * 2002-11-12 2011-12-06 Epitomics, Inc. Method for identifying differentially expressed proteins
WO2004082605A2 (en) 2003-03-14 2004-09-30 Merck & Co. Inc. Bicyclic anilide spirohydantoin cgrp receptor antagonists
SI2163260T1 (sl) 2004-01-23 2017-07-31 Msd Italia S.R.L. Nosilci šimpanzjih adenovirusnih cepiv
US7659300B2 (en) 2004-09-08 2010-02-09 Merck Sharp & Dohme Corp. Monocyclic anilide spirolactam CGRP receptor antagonists
US8099179B2 (en) 2004-09-10 2012-01-17 GM Global Technology Operations LLC Fault tolerant control system
AU2006284756B2 (en) * 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
BRPI0619665B1 (pt) * 2005-11-08 2022-04-12 University Of Cape Town Método para melhorar a expressão de um transgene em uma célula hospedeira in vitro, cassete de expressão em mamífero, vetor, vacina de dna e composição farmacêutica
CN101484466A (zh) 2006-02-16 2009-07-15 美国国有健康与人类服务部(马里兰州) 针对流感病毒的抗病毒剂和疫苗
BRPI0711352A2 (pt) 2006-05-09 2011-09-27 Merck & Co Inc composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular
US8148390B2 (en) 2007-03-12 2012-04-03 Merck, Sharp & Dohme, Corp. Monocyclic anilide spirolactam CGRP receptor antagonists

Also Published As

Publication number Publication date
US9017696B2 (en) 2015-04-28
CA2683679A1 (en) 2008-10-16
GB0717888D0 (en) 2007-10-24
US20150297700A1 (en) 2015-10-22
WO2008122811A3 (en) 2009-01-22
EP2176418A2 (en) 2010-04-21
EP2486939B1 (en) 2017-07-12
WO2008122769A2 (en) 2008-10-16
AU2008235363A1 (en) 2008-10-16
CN101848729A (zh) 2010-09-29
EP2486939A1 (en) 2012-08-15
EP2176418B1 (en) 2017-08-16
WO2008122811A2 (en) 2008-10-16
US9895431B1 (en) 2018-02-20
US10124048B2 (en) 2018-11-13
MX2009010870A (es) 2010-02-17
WO2008122769A3 (en) 2009-01-22
EP2160197B1 (en) 2016-09-21
JP2010523137A (ja) 2010-07-15
GB0706914D0 (en) 2007-05-16
US20120058138A1 (en) 2012-03-08
JP5505937B2 (ja) 2014-05-28
EP2160197A2 (en) 2010-03-10
AU2008235363B2 (en) 2013-05-16
ES2638577T3 (es) 2017-10-23
ES2606365T3 (es) 2017-03-23

Similar Documents

Publication Publication Date Title
BRPI0906997A2 (pt) Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica
BR112012004823A2 (pt) composto de ligação, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira, métodos pra produzir um polipeptídeo e para intensificar uma resposta imune em um sujeiro humano, composição farmacêutica, e, anticorpo ou fragmento de ligação de antígeno
BRPI0815836A2 (pt) Construção de antígeno-vetor de fluorocarboneto, vetor de fluorocarboneto, composição farmacêutica, uso da construção, e, métodos de tratamento ou imunização, para estimular uma resposta imune, e para preparar uma resposta farmacêutica profilática ou terapêutica.
NO344947B1 (no) Peptistoffsammensetninger og fremgangsmåter for fremstilling av lyofiliserte sammensetninger som omfatter et peptistoff, samt et sett som omfatter peptistoff sammensetningene.
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
BRPI0819995A2 (pt) Válvulas de múltiplas posições para controle de areia e fratura, e métodos de acabamento associados.
PA8750301A1 (es) 4-[ 4{ 4-cloro-3-(trifluorometil)fenil] carbamoil}amino)-3-fluorofenoxi] -n-metilpiridin-2-carboxamida monohidratada
BRPI0815919A2 (pt) Formulação tópica local, uso de uma formulação, e, método para o controle de um ectoparasita sobre um animal doméstico.
BRPI0809125A2 (pt) composições sinergísticas para controle de pragas
BRPI0721003A2 (pt) Polinucleotídeo; vetor; célula recombinante; polipeptídeo; anticorpo; composição; composição preparada por um processo; uso da composição; método para preparar uma composição; método para preparar uma composição de anticorpo; método para induzir uma resposta imune em um mamífero; e método para prevenir ou tratar meningite bacteriana em um mamífero.
BRPI0719014A2 (pt) Formulações de fungos entomopatogênicos para controle de insento
EP1951281A4 (en) WT1 HLA CLASS II BINDING SPEPTIDES AND THESE COMPREHENSIVE COMPOSITIONS AND METHOD
BRPI0923500A2 (pt) uso e composição farmacêutica compreendendo agonista ou modulador do receptor s1p, e kit.
EP2225275A4 (en) PROTEIN FORMULATION
DK2035447T3 (da) Polypeptid
BRPI0810913A2 (pt) Válvula, em particular, válvula de cola
FI20060858L (fi) Ilma-aluksen kaarielementti, siipi, ohjainpinta sekä vakaaja
IL210589A0 (en) The tuberculosis rv2386c protein, compositions and uses thereof
BRPI0816248A2 (pt) Aparelho de disco de vedação para uso com uma válvula, membro de controle de fluidos para uso com uma válvula, e, regulador de fluidos
BRPI0820157A2 (pt) Válvula de controle, retentor pára uma válvula de controle, e, métodos para montar uma válvula de controle
BRPI0914147A2 (pt) composição herbicidas, uso das composições, método para controlar vegetação indesejável, e, formulação herbicida.
BRPI0810710A2 (pt) Método para estabilização de uma proteína.
BRPI0807126A2 (pt) Aglutinantes quosos de revestimento para proteção contra corrosão, madeira e concreto
EP2069386A4 (en) PROTEIN MOLECULAR WEIGHT STANDARDS WITH HIGH DISINFECTION
BRPI0823213A2 (pt) Método de controle do código de uma aeronave.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]